Research Article
Clinical Features, Treatment, and Outcome in 102 Adult and Pediatric Patients with Localized High-Grade Synovial Sarcoma
Table 3
Univariate analysis of prognostic factors in adult and pediatric SS.
| Variable | | 5-year EFS | n | P |
| Size | <5 cm | 62 ± 6.3% | 35 | .03 | ≥5 cm | 82 ± 6.7% | 65 |
| Depth | Superficial | 81.8 ± 11.6% | 12 | .35 | Deep | 69.1 ± 5.1% | 89 |
| Microscopic margin status | Positive | 62.5 ± 17.1% | 94 | .62 | Negative | 70.4 ± 5.0% | 8 |
| Center | Pediatric | 74.9 ± 13.0% | 15 | .31 | Adult | 68.7 ± 5.1% | 87 |
| Age | ≤30 | 70.9 ± 6.7% | 51 | .47 | >30 | 68.6 ± 6.8% | 51 |
| Bone invasion | Present | 45 ± 17.4% | 10 | .02 | Absent | 74.5 ± 5.1% | 80 |
| Neurovascular invasion | Present | 60.0 ± 21.9% | 6 | .87 | Absent | 71.8 ± 5.2% | 84 |
| Radiation | Yes | 69.6 ± 5.4% | 80 | .67 | No | 67.5 ±11% | 21 |
| Chemotherapy | Yes | 62.6 ± 11.2% | 25 | .48 | No | 71.5 ± 5.3% | 77 |
| Adults | Chemotherapy | 56.3 ± 14.8% | 12 | .13 | No chemo | 70.7 ± 5.4% | 75 |
| Pediatric | Chemotherapy | 69.2 ± 15.6% | 13 | .41 | No chemo | 100% | 2 |
| >5 cm | Chemotherapy | 51.3 ±13.4% | 19 | .37 | No chemo | 65.7 ±7.2% | 46 |
|
|